Ex Parte

Ex Parte is litigation intelligence software for finding potential vulnerabilities in legal cases. It best suits legal and investment teams working across patent, court, technical, and financial records. Source-linked findings are its strongest practical advantage; trial constraints and the need to verify outputs weigh against relying on it without review.

Overview

Each matter gets a secure, permissioned workspace, and reports connect findings to source pages, lines, and citations. That makes it easier for a reviewer to inspect the record behind an analytical conclusion, an important distinction for consequential legal work.

Ex Parte combines legal records with technical, scientific, and financial sources, including USPTO file wrappers, PTAB proceedings, PACER filings, court opinions and dockets, IEEE Xplore, ACM Digital Library, PubMed, and SEC EDGAR. The company says its entity graph contains more than 2 billion entities and its knowledge graph maps more than 2 billion relationships connecting patents, parties, counsel, judges, and outcomes. Such breadth suits matters spanning multiple domains, but graph size alone does not establish the reliability of a finding.

Key features

Focused forensic analysis

Domain-specific agents analyze examiner search logs, prosecution history amendments, and mismatches between complaint allegations and patent specifications. These targeted checks make the product relevant to patent disputes and related case assessment; they are not a substitute for legal judgment or independent verification.

Source checks and analytics

Ex Parte says a dedicated quality-review agent checks every finding against primary sources before delivery. Reports preserve source links for human review, while the trial terms caution that generated outputs are probabilistic, may contain errors, and do not constitute legal advice. Judge, outcome, attorney and party, and case trend analytics extend the offering beyond document review to broader case assessment.

Pricing

Ex Parte is paid, with custom pricing available on request. Paid enterprise subscriptions are governed by a separately negotiated Master Services Agreement, so prospective customers should expect to discuss terms with the company rather than select a published tier.

A free trial requires no credit card. Verified law firm and corporate domains receive immediate approval, making it a practical route for eligible teams to evaluate the workflow before negotiating enterprise terms. The trial is for internal evaluation only, may be rate-limited or suspended, and comes with no service levels or support. Customer input may be permanently deleted after the trial period. Trial users must not submit sensitive or regulated data; the trial has no data processing addendum or security warranty. These constraints make the trial unsuitable for production work or testing on confidential matter material.

Platforms

Ex Parte runs on the web. Its matter-based workspace and research sources are therefore accessed through a browser rather than a dedicated mobile or desktop platform.

Who it's for

The company identifies law firms, corporate counsel, litigation finance, hedge funds, insurers, and universities as audiences. It is most compelling for teams assessing consequential matters that benefit from linking legal analysis to technical, scientific, or financial records. Firms and counsel handling sensitive live matters should weigh the trial's data restrictions and lack of support carefully, and should confirm the protections and service commitments in negotiated enterprise terms.

Pros and cons

Pros

Findings are tied to source pages, lines, and citations: reviewers can trace conclusions to underlying records.

Broad legal and cross-domain coverage: the knowledge graph spans court and patent records alongside scientific, technical, and financial sources.

Specialized case checks and analytics: examiner logs, prosecution amendments, allegation/specification mismatches, and judge and outcome analytics address concrete litigation questions.

No-card evaluation path: eligible verified law firm and corporate domains receive immediate trial approval.

Cons

Custom enterprise pricing: buyers cannot compare a published per-seat rate or plan tiers before contacting the company.

Trial is not production-ready: it can be rate-limited or suspended, has no support or service levels, and forbids sensitive or regulated data.

Outputs require verification: probabilistic findings may contain errors and are not legal advice.

Trial data may be deleted: customer input may not persist after the evaluation period.

Alternatives

Legal Case Analytics Software is the broader category to compare when evaluating tools for this type of work. Choose UpLaw if a free legal research option and published lower-cost paid access matter more than Ex Parte's focused matter workspaces and forensic analysis. Docket Alarm is a better fit for buyers who want freemium access to docket searches and document views, including API and web platforms. Consider LegalLink for its published annual plan centered on Australian case access, AI consultations, case summaries, and judge preference insights. Cubictree Litigation Data Analytics is another paid litigation-data option, with Android, iOS, web, API, and self-hosted platforms.

Lexis+ is worth considering for organizations seeking a paid legal research subscription with a free trial and organization-dependent pricing. CaseRadar suits buyers looking for a published $99 a month entry plan with one seat, judge analytics, outcome prediction, case summaries, and PDF export. For patent-library subscriptions, compare Docket Navigator, which offers individual subscriptions for sole proprietors and group pricing by user count. CLARA Litigation is another paid litigation option to consider.

Verdict

Choose Ex Parte if your legal or investment team needs matter-level analysis that connects potential case vulnerabilities to underlying sources across legal and adjacent research domains. Its traceable findings and targeted forensic checks are the clearest reasons to consider it. Look elsewhere if you need transparent published pricing, trial support and service commitments, or a trial suitable for sensitive data; in any evaluation, treat outputs as leads for independent review, not final legal conclusions.